Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis

Hepatitis B (HBV) reactivation was observed to be more than 10% in patients receiving interferon-based therapy for hepatitis C (HCV) co-infection. At present, when direct-acting antiviral (DAA) has become the main treatment for HCV, there are few large-scale studies on the reactivation of HBV in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Oh, Joo Hyun, Park, Dong Ah, Ko, Min Jung, Yoo, Jeong-Ju, Yim, Sun Young, Ahn, Ji-Hyun, Jun, Dae Won, Ahn, Sang Bong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781230/
https://www.ncbi.nlm.nih.gov/pubmed/36556178
http://dx.doi.org/10.3390/jpm12121957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781230/
https://www.ncbi.nlm.nih.gov/pubmed/36556178
http://dx.doi.org/10.3390/jpm12121957

Ejemplares similares